tbuckley/cabot-search huggingface dataset:
Coexpression of Bmi-1 and Interleukin-3 Receptor Alpha Chain (CD123) Correlate with Poor Prognosis In Acute Myeloid Leukemia
Authors: Jaroslaw Dybko, Donata Urbaniak-Kujda, Katarzyna Kapelko-Slowik, Kazimierz Kuliczkowski
Journal: Blood (2010)
MA07.10 HDAC Inhibition Overcomes Crizotinib-Resistance by Mesenchymal-Epithelial Transition (MET) in EML4-ALK Lung Cancer Cells
Authors: Koji Fukuda, Shinji Takeuchi, Ryohei Katayama, Shigeki Nanjo, Tadaaki Yamada, Takeshi Suzuki, Kengo Takeuchi, Makoto Nishio, Seiji Yano
Journal: Journal of Thoracic Oncology (2017)
S82 Bone marrow transplantation reduces susceptibility to pulmonary hypertension in BMPR2 deficient mice
Authors: A Crosby, E Soon, M Southwood, BJ Dunmore, M Toshner, NW Morrell
Journal: Thorax (2016)

<h3>Introduction</h3> Increasing evidence suggests that patients with pulmonary arterial hypertension (PAH) have abnormalities in the bone marrow (BM). Approximately 40% of patients with PAH are reported to have evidence of myelodysplasia. Conversely PAH is often found (13–48%) in patients with myeloproliferative disease. In a bone marrow transplant (BMT) model it has been shown that mice transplanted with CD133+ cells from PAH patients developed pulmonary vascular remodelling and right ventricular hypertrophy; whereas, CD133+ cells from controls did not. CD133+ cells from PAH patients also showed greater myeloid commitment. Since mutation in the bone morphogenetic protein receptor type 2 (BMPR2) is the commonest genetic cause of PAH we questioned whether bone marrow transplantation of wild type bone marrow reduces the susceptibility to PAH in the BMPR2 heterozygous mouse. <h3>Methods</h3> WT mice were transplanted with BMPR2 ± BM and BMPR2 ± mice were transplanted with WT BM. Sixteen weeks post-transplant mice were exposed to low-dose chronic LPS (0.5 mg/kg 3 times a week for 6 weeks), which we recently showed is a potent stimulus for the development of PAH in the BMPR2 heterozygous mouse. Mice underwent right heart catheterisation. Tissues were removed for histology. <h3>Results</h3> We observed a significant increase in RVSP when WT mice were transplanted with BMPR2 ± bone marrow after chronic LPS dosing. There was an increase in spleen weight and circulating platelets in WT mice with BMPR2 ± bone marrow and a converse reduction in spleen weight and platelets in BMPR2 ± mice with WT BM. Bone marrow histology demonstrated reduced myeloid cells and megakaryocytes, iron deposition and fibrosis related to LPS administration. In preventative studies BMPR2 ± mice transplanted with WT bone marrow did not develop significant pulmonary hypertension after chronic LPS exposure. <h3>Conclusions</h3> The susceptibility to PAH in the BMPR2 heterozygous mouse can be conferred on a wild type animal by bone marrow transplantation of BMPR2 deficient bone marrow. Transplanting WT BM into BMPR2 ± mice prevented PAH. The role of bone marrow derived cells in the pathobiology of PAH requires further elucidation, but may point to a potential future treatment
Managers must respond to doctors’ patient safety concerns, GMC says
Authors: Tom Moberly
Journal: BMJ (2017)

Doctors must continue to highlight risks to the safety of patients as pressure on services mounts,1 and health service managers must respond to these concerns, the UK General Medical Council has said.

Charlie Massey, the GMC’s chief executive, said that the regulator recognised that doctors across the United Kingdom were doing their utmost to maintain standards of care for patients. “They are telling us that there is unprecedented demand on services and that concerted action is now needed …
A Prospective Study of G-CSF Primed Bone Marrow from Pediatric Donors as a Stem Cell Source for Allogeneic Bone Marrow Transplant: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study.
Authors: Haydar Frangoul, Ann Woolfrey, Shakila Khan, Michael Pulsipher, John Levine, David Baker, Mark Walters, Mouhab Ayas, Yaddanapudi Ravindranath, Stephan Grupp, Dean Billheimer, Eneida Nemecek
Journal: Blood (2005)
PUB111 Delineating Mediastinal Lymph Nodal Clinical Target Volume: Comparison of Two Atlases and Practical Implications
Authors: Maria Taraborrelli, Marianna Nuzzo, Annamaria Vinciguerra, Antonietta Augurio, Francesca Perrotti, Saide Di Biase, Clelia Di Carlo, Domenico Genovesi
Journal: Journal of Thoracic Oncology (2017)
Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in <i>BRCA1/2</i>–wild-type Triple-Negative Breast Cancer
Authors: Thomas M. Cardillo, Robert M. Sharkey, Diane L. Rossi, Roberto Arrojo, Ali A. Mostafa, David M. Goldenberg
Journal: Clinical Cancer Research (2017)

Purpose: Both PARP inhibitors (PARPi) and sacituzumab govitecan (IMMU-132) are currently under clinical evaluation in triple-negative breast cancer (TNBC). We sought to investigate the combined DNA-damaging effects of the topoisomerase I (Topo I)-inhibitory activity of IMMU-132 with PARPi disruption of DNA repair in TNBC.Experimental Design:In vitro, human TNBC cell lines were incubated with IMMU-132 and various PARPi (olaparib, rucaparib, or talazoparib) to determine the effect on growth, double-stranded DNA (dsDNA) breaks, and cell-cycle arrest. Mice bearing BRCA1/2-mutated or -wild-type human TNBC tumor xenografts were treated with the combination of IMMU-132 and PARPi (olaparib or talazoparib). Study survival endpoint was tumor progression to >1.0 cm3 and tolerability assessed by hematologic changes.Results: Combining IMMU-132 in TNBC with all three different PARPi results in synergistic growth inhibition, increased dsDNA breaks, and accumulation of cells in the S-phase of the cell cycle, regardless of BRCA1/2 status. A combination of IMMU-132 plus olaparib or talazoparib produces significantly improved antitumor effects and delay in time-to-tumor progression compared with monotherapy in mice bearing BRCA1/2-mutated HCC1806 TNBC tumors. Furthermore, in mice bearing BRCA1/2-wild-type tumors (MDA-MB-468 or MDA-MB-231), the combination of IMMU-132 plus olaparib imparts a significant antitumor effect and survival benefit above that achieved with monotherapy. Most importantly, this combination was well tolerated, with no substantial changes in hematologic parameters.Conclusions: These data demonstrate the added benefit of combining Topo I inhibition mediated by IMMU-132 with synthetic lethality provided by PARPi in TNBC, regardless of BRCA1/2 status, thus supporting the rationale for such a combination clinically. Clin Cancer Res; 23(13); 3405-15. ©2017 AACR.
Evolution of Prognosis in Left-Sided Infective Endocarditis
Authors: Teresa Sevilla, Javier López, Itziar Gómez, Isidre Vilacosta, Cristina Sarriá, Pablo Elpidio García-Granja, Carmen Olmos, Salvatore Di Stefano, Luis Maroto, José Alberto San Román
Journal: Journal of the American College of Cardiology (2017)
P1.02-067 Repeated Biopsy for Immunohistochemical and Mutational Analysis of Non-Small Cell Lung Cancer: Feasibility and Safety
Authors: Mariona Riudavets, Georgia Anguera, Alfons Torrego, Virginia Pajares, Ana Gimenez, Laura López Vilaró, Elisabeth Martínez Tellez, Joan Carles Trujillo, Núria Farré, Enrique Lerma, Josep Belda, Valle Camacho, Alejandro Fernandez, Ana Muñoz, Margarita Majem
Journal: Journal of Thoracic Oncology (2017)
P3.04-003 Incidence and Outcome of Female Patients with Previous Breast Cancer Undergoing Curative Resection for Lung Cancer
Authors: Sabrina Tahon, Ariane Steindl, Mai Nguyen, Balazs Dome, Viktoria Laszlo, Walter Klepetko, Thomas Klikovits, Mir Hoda
Journal: Journal of Thoracic Oncology (2017)
P1.04-020 Management of Lung Cancer in Patients with past Pulmonary Tuberculosis and Their Possible Causative Link
Authors: Fatmir Caushi, Jona Shkurti, Danjela Xhemalaj, Ilir Skenduli, Arjan Mezini, Hasan Hafizi, Alban Hatibi, Irma Bani
Journal: Journal of Thoracic Oncology (2017)
Salvage Therapies in Patients with High-Risk Relapse After Fludarabine, Cyclophosphamide, Rituximab (FCR) for Chronic Lymphocytic Leukemia: The French CLL Intergroup Experience
Authors: Luc-Matthieu Fornecker, Therese Aurran-Schleinitz, Anne-Sophie Michallet, Bruno Cazin, Jehan Dupuis, Romain Guieze, Marie-Sarah Dilhuydy, Jean-Marc Zini, Cécile Tomowiak, Stéphane Leprêtre, Florence Cymbalista, Annie Brion, Pierre Feugier, Veronique Leblond, Loic Ysebaert
Journal: Blood (2012)
Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (VELCADE®, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with VELCADE for Newly Diagnosed Multiple Myeloma: Interim Results of Phase II Trial.
Authors: Sung-Soo Yoon, Hye Jin Kim, Dong Soon Lee, Hyeon Seok Eom, Jun Ho Jang, Ju Seup Chung, Hye Jin Kang, Cheol Soo Kim, Kihyun Kim, Jae Hoon Lee, Sang Jae Lee, Yu Hong Min, Chu Myong Seong, Sang Kyun Sohn, Cheolwon Suh, Jong Ho Won
Journal: Blood (2007)
P2.03b-085 Programmed Cell Death Ligand 1 (PD-L1) Expression in Stage II and III Lung Adenocarcinomas
Authors: Hironori Uruga, Takeshi Fujii, Shuhei Moriguchi, Yui Takahashi, Kazumasa Ogawa, Ryoko Murase, Sayaka Mochizuki, Shigeo Hanada, Hisashi Takaya, Atsushi Miyamoto, Nasa Morokawa, Sakashi Fujimori, Tadasu Kono, Kazuma Kishi
Journal: Journal of Thoracic Oncology (2017)
Cytomegalovirus Seropositivity Does Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation with Intensive Monitoring and Modern Anti-Viral Therapy
Authors: S. Singhal, Rucha Mehta, J. Krishnamurthy, S. Duffey, O. Frankfurt, Andrew M Evens, J. Altman, M. Tallman, L. Gordon, S. Williams, J. Winter, J. Mehta
Journal: Blood (2008)
Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study
Authors: Emilia Pardal, Eva Diez-Baeza, Eva González-Barca, Tomas Garcia-Cerecedo, Encarna Monzo, Juan-Manuel Sancho, Jose Maria Moraleda, Raul Cordoba, Fatima De la Cruz, JA Queizan, Maria Rodriguez-Salazar, JA Hernández-Rivas, Belen Navarro, Rosana Diez-Angulo, Maria Cruz Viguria, Maria Vahi, Maria Jesús Peñarrubia, Monica Sanchez, Miguel Canales, Tomas Gonzalez, Sara Alonso, Maria Dolores Caballero, Alejandro Martin
Journal: Blood (2015)
MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas
Authors: Katherine Hastings, Jungmin Choi, Anna Wurtz, Zenta Walther, Guoping Cai, Isabel Oliva, Ziming Zhao, Stephen Gaffney, Atila Iamarino, Siming Zhao, Mark Bi, Sarah Goldberg, Anne Chiang, Zongzhi Liu, Jeffrey Townsend, Joseph Schlessinger, Richard Lifton, Roy Herbst, Scott Gettinger, Katerina Politi
Journal: Journal of Thoracic Oncology (2017)
P3.02b-007 Differential Efficacy of Gefitinib in Exon 19 or Exon 21 Mutated Adenocarcinoma Lung
Authors: Alok Goel, Amit Joshi, Vijay Patil, Vanita Noronha, Anuradha Chougule, Abhishek Mahajan, Amit Janu, Rajiv Kaushal, Supriya Goud, Sucheta More, Ashay Karpe, Anant Ramaswamy, Nikhil Pande, Arun Chandrasekharan, Vikas Talreja, Raajit Chanana, Kumar Prabhash
Journal: Journal of Thoracic Oncology (2017)
FVIII Recovery after a Single Infusion of Recalibrated ReFacto in 14 Severe Hemophilia A Patients.
Authors: Thierry Lambert, Claude Guérois, Valerie Gay, Natalie Stieltjes, Marie-Anne Bertrand, Annie Derlon, Marianne Sigaud, Abel Hassoun, Claude Négrier, Brigitte Coatmelec, Marie Dreyfus, Arnaud Dubanchet
Journal: Blood (2005)
Pharmacokinetics-Based Modification of Intravenous Pegylated Asparaginase Dosing in the Context of a “Pediatric-inspired” Protocol in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Authors: Dan Douer, Ibrahim Aldoss, Matthew A Lunning, Laleh Ramezani, Patrick Burke, Lisa Mark, Janice Vrona, Jae H. Park, Martin S Tallman, Vinod Pullarkat, Ann M Mohrbacher, Vassilos I Avramis
Journal: Blood (2012)
P3.03-030 Cisplatin with Pemetrexed or Gemcitabine in Prolonged Infusion for Inoperable Mesothelioma: A Phase II Randomized Trial
Authors: Viljem Kovac, Matjaz Zwitter, Danijela Strbac, Katja Goricar, Ales Rozman, Izidor Kern, Mirjana Rajer
Journal: Journal of Thoracic Oncology (2017)
Clofarabine in Combination with Etoposide and Cyclophosphamide (CLOVE) in Pediatric Patients with Relapsed Acute Leukemia: 4 Italian Pediatric AIEOP Centers’ Experience
Authors: Concetta Micalizzi, Rosanna Parasole, Maria Caterina Putti, Matteo Luciani, Laura Banov, Fara Petruzziello, Chiara Messina, Giulio De Rossi
Journal: Blood (2008)
P3.02b-018 Detection of Epidermal Growth Factor Receptor Mutations in Circulating Cell-Free DNA versus Tumor Biopsy
Authors: In-Jae Oh, Hyeong-Won Seo, Hyun-Ju Cho, Tae-Ok Kim, Cheol-Kyu Park, Jung-Hwan Lim, Young-Chul Kim, Ju-Sik Yun, Sang-Yun Song, Kook-Joo Na, Mee-Sun Yoon, Sung-Ja Ahn, Hyun-Ju Seon, Seong Young Kwon, Yoo-Duk Choi
Journal: Journal of Thoracic Oncology (2017)
JCES01.23 EGFR Mutation Status Analysis in Cerebrospinal Fluid and Plasma of Advanced Lung Adenocarcinoma with Brain Metastases
Authors: Liang Shi, Zhe Liu, Jungfang Tang, Hongbo Wu, Lili Guo, Mingzhi Li, Li Tong, Wei Wu, Hong Tao, Weihua Wu, Hongxia Li, Qiyi Meng, Liyan Xu, Yunzhong Zhu
Journal: Journal of Thoracic Oncology (2017)
Post-Induction Minimal Residual Disease (MRD) Defines a Large Subset of Adults with Favorable Ph-Negative Acute Lymphoblastic Leukemia (ALL), Who Do Not Benefit From Allogeneic Stem Cell Transplantation (SCT) in First Complete Remission: A GRAALL Study.
Authors: Kheira Beldjord, Véronique Lhéritier, Marie-Laure Boulland, Nathalie Grardel, Jean-Michel Cayuela, Hélène Cavé, Beat Schäfer, Marleen Bakkus, Marlène Garrido, Nathalie Dhédin, Anne Huynh, Thibaut Leguay, Claude Gardin, Xavier Thomas, Yves Chalandon, Françoise Huguet, Jean-Paul Vernant, Thierry Fest, Norbert Ifrah, Elizabeth Macintyre, Hervé Dombret
Journal: Blood (2009)
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial
Authors: Meike H van der Ree, J Marleen de Vree, Femke Stelma, Sophie Willemse, Marc van der Valk, Svend Rietdijk, Richard Molenkamp, Janke Schinkel, Ad C van Nuenen, Ulrich Beuers, Salah Hadi, Marten Harbers, Eva van der Veer, Kai Liu, John Grundy, Amy K Patick, Adam Pavlicek, Jacqueline Blem, Michael Huang, Paul Grint, Steven Neben, Neil W Gibson, Neeltje A Kootstra, Hendrik W Reesink
Journal: The Lancet (2017)
BRAFV600E Mutations Occur In The Hematopoietic Stem Cell Compartment In Hairy Cell Leukemia
Authors: Stephen S. Chung, Jae H. Park, Eunhee Kim, Young Rock Chung, Wenhuo Hu, Piro Lito, Julie Teruya Feldstein, Raajit K. Rampal, Leon Telis, Minal Patel, Neal Rosen, Christopher Y. Park, Martin S. Tallman, Omar Abdel-Wahab
Journal: Blood (2013)
Effects of Cabozantinib Alone and in Combination with Bortezomib in the 5TGM1 Murine Multiple Myeloma Model
Authors: Dana T. Aftab, Mari I. Suominen, Douglas O. Clary, Rami Käkönen, Katja M. Fagerlund, Esa Alhoniemi, Jukka P. Rissanen, Jussi M. Halleen
Journal: Blood (2014)
P2.03a-008 Relative Dose Intensity of First-Line Chemotherapy and Overall Survival in Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC)
Authors: Neelima Denduluri, Debra Patt, Xiaolong Jiao, Phuong Morrow, Jacob Garcia, Rich Barron, Jeffrey Crawford, Gary Lyman
Journal: Journal of Thoracic Oncology (2017)
PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study
Authors: Marina Garassino, Johan Vansteenkiste, Joo-Hang Kim, Hervé Léna, Julien Mazières, John Powderly, Phillip Dennis, Yifan Huang, Catherine Wadsworth, Naiyer Rizvi
Journal: Journal of Thoracic Oncology (2017)
Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies
Authors: Heikki Kuusanmäki, Hanna Rajala, Arjan van Adrichem, Muntasir Mamun Majumder, Emma I Andersson, Krister Wennerberg, Satu Mustjoki, Caroline A Heckman
Journal: Blood (2014)
Learning from appraisal could help to spot doctors in difficulty, say researchers
Authors: Abi Rimmer
Journal: BMJ (2017)

A group of researchers are seeking to gather doctors’ experiences of appraisal and revalidation in a bid to see if more can be done to spot those who are in difficulty sooner.

Researchers want to recruit around 20 doctors who have completed the fitness to practise (FTP) process after being referred by their employer.

Julian Archer is director of the Collaboration for the Advancement of Medical Education, Research and Assessment (CAMERA) …
The Majority of RAS Pathway Mutations Detected in Relapsed B-Cell Precursor Acute Lymphoblastic Leukemia Are Present in Major or Minor Subclones at Diagnosis
Authors: Jiangyan Yu, Esmé Waanders, Simon V. van Reijmersdal, Edwin Sonneveld, Peter M Hoogerbrugge, Frank N. van Leeuwen, Ad Geurts van Kessel, Roland P. Kuiper
Journal: Blood (2014)
Evaluation of Dual Tracer (FLT and FDG) PET Imaging As Part of Risk-Adapted Therapy for Patients with Advanced Stage Diffuse Large B Cell Lymphoma (DLBCL)
Authors: Craig H. Moskowitz, Heiko Schoder, Paul Hamlin, Jocelyn C Maragulia, Janelle Walkley, Andrew D. Zelenetz
Journal: Blood (2012)
Beta7 Integrins Regulate Podia Formation in Multiple Myeloma (MM) Cells for the Interaction with the Cellular and Non-Cellular Bone Marrow (BM) Stroma
Authors: Karthik Ramasamy, Henry Lekgetho, Jose Luis Orgaz, Amna Anwar, Victoria Sanz-Moreno, Majid A Kazmi, Stephen Schey, Yolanda Calle
Journal: Blood (2012)
Hierarchical Clustering of B-Cell Receptor Structures in Splenic Marginal Zone Lymphoma
Authors: Paolo Marcatili, Silvia Zibellini, Sara Rattotti, Anna Chailyan, Marzia Varettoni, Lucia Morello, Emanuela Boveri, Marco Lucioni, Maurizio Bonfichi, Manuel Gotti, Valeria Fiaccadori, Marco Paulli, Anna Tramontano, Luca Arcaini
Journal: Blood (2012)
P3.02c-028 Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC)
Authors: Stephen Bagley, Shawn Kothari, Charu Aggarwal, Joshua Bauml, Evan Alley, Tracey Evans, John Kosteva, Christine Ciunci, Jeffrey Thompson, Susan Stonehouse-Lee, Victoria Sherry, Elizabeth Gilbert, Beth Eaby-Sandy, Faith Mutale, Gloria Dilullo, Roger Cohen, Anil Vachani, Corey Langer
Journal: Journal of Thoracic Oncology (2017)
Nuclear microRNAs in normal hemopoiesis and cancer
Authors: John E.J. Rasko, Justin J.-L. Wong
Journal: Journal of Hematology & Oncology (2017)

Since the discovery of microRNAs (miRNAs) in the early 1990s, these small molecules have been increasingly recognized as key players in the regulation of critical biological processes. They have also been implicated in many diverse human diseases. The canonical function of miRNAs is to target the 3′ untranslated region (3′ UTR) of cytoplasmic messenger RNA to post-transcriptionally regulate mRNA and protein levels. It has now been shown that miRNAs can also bind to the promoter regions of genes or primary miRNA transcripts to regulate gene expression. Such observations have indicated the presence of miRNAs in the nucleus and implied additional non-canonical functions. Nevertheless, the role(s) of nuclear miRNAs in normal hemopoiesis and cancer remains elusive despite a burgeoning literature. Herein, we review current knowledge concerning the abundance and/or functions of nuclear miRNAs during blood cell development and cancer biology. We also discuss ongoing challenges in order to provoke further studies into identifying key roles for nuclear miRNAs in the development of other cell lineages and human cancers.
MA14.06 Nivolumab in Never Smoker Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP)
Authors: Giuseppe Lo Russo, Lucio Crinò, Domenico Galetta, Andrea Ardizzoni, Enrico Cortesi, Frederico Cappuzzo, Paola Bordi, Luana Calabrò, Fausto Barbieri, Antonio Santo, Giuseppe Altavilla, Giacomo Cartenì, Enrico Mini, Enrico Vasile, Floriana Morgillo, Alessandro Scoppola, Carmelo Bengala, Gianpiero Fasola, Natale Tedde, Francovito Piantedosi
Journal: Journal of Thoracic Oncology (2017)
P3.02b-067 A Single-Institution Experience of Afatinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Authors: Hiroyuki Minemura, Hiroshi Yokouchi, Kenichiro Hirai, Tatsuhiko Koizumi, Kenya Kanazawa, Yoshinori Tanino, Mitsuru Munakata
Journal: Journal of Thoracic Oncology (2017)
Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy.
Authors: Jorge Sierra, Montserrat Hoyos, Josep F. Nomdedeu, Jordi Esteve, Rafael F. Duarte, Josep-Maria Ribera, Mar Tormo, Ramon Guardia, Andreu Llorente, Javier Bueno, Juan Besalduch, M. Paz Queipo, Josep M. Marti-Tutusaus, Carmen Pedro, Pio Torres, Antoni Garcia, Inmaculada Heras, Joan Bargay, Llorenç Font, Jose Gonzalez, Antonia Sampol, Olga Salamero, Lourdes Escoda, David Gallardo, Marisa Calabuig, Albert Oriol, Montserrat Arnan, Marta Pratcorona, Salut Brunet
Journal: Blood (2010)
P1.08-077 Comparison of Pulmonary Resection for Lung Cancer after Radical Chemoradiation with That after Induction Chemoradiation
Authors: Yasuhiro Hida, Kichizo Kaga, Masato Aragaki, Reiko Nakada-Kubota, Haruhiko Shiiya, Hatsuki Usui, Yoshiro Matsui
Journal: Journal of Thoracic Oncology (2017)
Predictors of the Use of Specific Critical Care Therapies in Patients With Metastatic Cancer
Authors: Kah Poh Loh, Ankit Kansagra, Meng-Shiou Shieh, Penelope Pekow, Peter Lindenauer, Mihaela Stefan, Tara Lagu
Journal: Journal of the National Comprehensive Cancer Network (2016)

Understanding which factors are associated with the use of critical care therapies (CCTs) can help with clinical decision-making and goals of care discussion. The goal of this study was to describe the predictors of CCT use (eg, mechanical ventilation, tracheostomy, percutaneous endoscopic gastrostomy tube, total parenteral nutrition, acute use of dialysis) in hospitalized patients with metastatic cancer.We used the 2010 California State Inpatient Databases sponsored by the Agency for Healthcare Research and Quality to identify all hospitalizations with a diagnosis of metastatic cancer (patients aged ≥18 years). We examined the predictors of any CCT use (and invasive mechanical ventilation [IMV] use), stratified by do-not-resuscitate (DNR) status, using multivariable logistic regression models.We identified 99,085 hospitalizations involving patients with metastatic cancer; 9.4% received any CCTs and 4.7% received IMV. Predictors of CCT use in the no-DNR group included principal diagnosis of infections (vs cancer-related), greater burden of comorbidities, and presence of weight loss. Predictors of CCT use in the DNR group were similar, but also included non-white races. Liver disease was also a predictor of IMV use in the no-DNR group. Patients with metastatic lung cancer (vs breast and genitourinary) with no DNR were more likely to receive CCT (and IMV).Higher burden of comorbidities, weight loss, liver disease, lung cancer subtype, and diagnosis of infections were associated with higher odds of receiving CCTs or IMV. These findings may help clinicians determine in whom to prioritize discussions around goals of care, especially in the group without a DNR status.
Association of Drug and Alcohol Use With Adolescent Firearm Homicide at Individual, Family, and Neighborhood Levels
Authors: Bernadette C. Hohl, Shari Wiley, Douglas J. Wiebe, Alison J. Culyba, Rebecca Drake, Charles C. Branas
Journal: JAMA Internal Medicine (2017)

Homicide is the third leading cause of death for adolescents in the United States and the leading cause of death for adolescents who are African American. Large cities have disproportionate homicide rates.
Increased Bone Marrow Iron Stores, Severe Mucositis and Large Area under the Curve (AUC) of Profound Neutropenia Predict Severe Infection in 382 Myeloma Patients Undergoing Melphalan - Autologous Stem Cell Transplantation (MEL-ASCT).
Authors: Elias J. Anaissie, Marisa H. Miceli, Li Dong, Monica L. Grazziutti, Sabitha Rajan, Giampaolo Talamo, Raymond Thertulien, Anasthasios Fassas, Guido Tricot, Bart Barlogie
Journal: Blood (2004)